Genovis (GENO) Q2 2026 earnings summary

Executive summary

• Achieved strategic expansion with the acquisition of KPL ApS, broadening the proteomics portfolio and customer base.

• Launched new products, including AlligBAITOR for antibody enrichment, and strengthened underlying profitability despite one-off acquisition costs.

• Product sales, excluding services, grew by approximately 20% year-over-year, with genomics delivering its best quarter to date.

Financial highlights

• Q2 net sales reached SEK 34,316 thousand, up 19% year-over-year (21% currency-adjusted); H1 net sales were SEK 67,823 thousand, up 11% (19% currency-adjusted).

• Q2 EBITDA was SEK 6,844 thousand, impacted by SEK 3,492 thousand in acquisition costs; adjusted EBITDA was SEK 10,336 thousand.

• Q2 EBIT was SEK 2,824 thousand; adjusted EBIT was SEK 6,316 thousand.

• Q2 earnings per share were SEK 0.02 (adjusted SEK 0.07); H1 EPS was SEK 0.08 (adjusted SEK 0.14).

• Q2 cash flow from operating activities was SEK 7,906 thousand; H1 cash flow was SEK 24,417 thousand.

Outlook and guidance

• Positioned for further advances in new products and sales in 2026, with most development projects on track.

• Business opportunities and operational capacity assessed as good, though external geopolitical and macroeconomic factors remain uncertainties.